SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally. The company offers an ultrasound technology that induces coagulation and subsequent revitalization for regenerated skin under the SUPERB brand; and non-invasive muscle toning technology under the Pure Impact VIP brand. It serves plastic surgeons, dermatologists, and other physicians who perform aesthetic treatments on patients. It also provides technical and clinical product support services. The company was incorporated in 2015 and is based in Yokneam Illit, Israel.
Frequently asked questions
What sector does Sofwave Medical Ltd (SOFW) operate in?
Sofwave Medical Ltd belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Sofwave Medical Ltd (SOFW) current stock price?
As of the latest data, Sofwave Medical Ltd stock price is ₪36.90, with a previous close of ₪36.11. Sofwave Medical Ltd gained ₪0.79 in the last trading session, representing a 2.19% increase.
What is Sofwave Medical Ltd (SOFW) current market capitalization?
Sofwave Medical Ltd market cap is approximately 1.34 billion.
What is Sofwave Medical Ltd (SOFW) Earnings Per Share (EPS)?
The trailing EPS is ₪0.60.
What is Sofwave Medical Ltd (SOFW) Price-to-Earnings (P/E) ratio?
Sofwave Medical Ltd current P/E ratio is 61.5.
What is Sofwave Medical Ltd (SOFW) EBITDA?
Sofwave Medical Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 3.35 million.
Does Sofwave Medical Ltd (SOFW) pay dividends?
No. Sofwave Medical Ltd does not pay a dividend.
What is Sofwave Medical Ltd (SOFW) beta (volatility) score?
Sofwave Medical Ltd has a beta of 0.652, indicating lower volatility than the overall market.
